ESMO 2024 | Phase I trial of PRT3789, a SMARCA2 degrader, in SMARCA4-mutated solid tumors
Guru Sonpavde, MD, AdventHealth Cancer Institute, Orlando, FL, discusses findings from a Phase I study (NCT05639751) of PRT3789, a selective SMARCA2 degrader, in patients with SMARCA4-mutated solid tumors. Early results show promising anti-tumor activity, including partial responses and prolonged stable disease, with no dose-limiting toxicities reported. The study highlights PRT3789’s potential for synthetic lethality in SMARCA4-mutated cancers, with dose escalation and backfill cohorts ongoing. Additional combinations strategies with pembrolizumab and docetaxel are being planned. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
